Sangon Biotech Co. (生工生物) is a leading force in biotechnology, specializing in chemically synthesized DNA. Since its founding in 2003, Sangon has emerged as a frontrunner in DNA synthesis and related advanced biotechnologies, articulated through their slogan: "Pioneering DNA synthesis and advanced biotechnologies since 2003".
Rooted as a high-tech Sino-foreign joint venture, the company strategically expanded in 2006 with a significant investment of 50 million to establish an industrial base at the Songjiang Industrial Park. Sangon's comprehensive product line encompasses DNA synthesis, DNA sequencing, gene synthesis, peptide synthesis, and several biotech essentials including molecular biology kits and lab consumables.
Recently, Sangon secured a major CNY2.00B Venture Round investment on 19 April 2023 from a distinguished cohort of investors, including Novo Holdings, Huagai Capital, Greenwoods Investment, GL Capital Group, among others. This backing signals strong confidence in Sangon's innovative trajectory and growth potential within the biotechnology sector.
Ansa Biotechnologies, Inc.
